Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Chimeric Therapeutics Limited (ASX: CHM)
ABN:	68 638 835 828

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Cindy Elkins
<b>Date of Last Notice:</b>	14 December 2021

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Indirect		
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Held via broker nominee account.		
Date of change	25 March 2	2022	
No. of securities held prior to change	Direct Indirect Total	Shares - 24,800 24,800	Options 2,750,000 - 2,750,000
Class		ully Paid Ordinary ested Options (AS)	
Number acquired	Direct Indirect Total	Shares - a) 7,873 7,873	Options  - b) 7,873 7,873
Number disposed	Direct Indirect Total	Shares -	Options -

<sup>+</sup> See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	a) \$0.17 pc b) Non-cas	er share. sh, see 'nature of c	hange' below.
No. of securities held after change		Shares	Options
	Direct	-	2,750,000
	Indirect	32,673	7,873
	Total	32,673	2,757,873
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	a & b) Participation in Entitlement Offer (with free attaching options) announced 21 February 2022.		

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

### Part 3 - Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A



The CFO Solution

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.